Cancer Genetics Team | NYU Langone Health
The High-Risk Cancer Genetics Program team at NYU Langone’s Perlmutter Cancer Center includes genetic counselors who specialize in cancer.
Medication for Laryngeal Cancer | NYU Langone Health
NYU Langone doctors may prescribe chemotherapy or targeted drugs to treat people with advanced laryngeal cancer.
A Phase II Study of DRP-104 a glutamine antagonist in patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer and Gastroesophageal Cancer
This is a Phase 2 study testing a new medicine called DRP-104 (a glutamine antagonist) in patients with non-small cell lung cancer (NSCLC). These patients have changes or mutations in genes called NFE2L2 orKEAP1 and this makes their cancer harder to treat with chemotherapy and immunotherapy.The medicine DRP-104 works by blocking something called glutamine, which the cancer cells need to grow. This study will use a two step process to see if the medicine works well in the first group, before allowing other patients to join. In step one, patients will be given DRP-104 two times a week with at least three days betweeneach treatment, with no rest period between cycles (continuous schedule). If the results are promising and show this medicine is shrinking the tumors or stopping them from growing, more patients will be added in step two tocontinue testing the drug. All patients will have frequent medical check ups and blood samples taken to see how their bodies are handling the study medicine. The study team will have special scans done for all patients to see how the cancer isresponding to the study medicines. The study team will be monitoring the patients for potential side effects and safety concerns.
Randomized Controlled Open-Label Parallel Group Multi-Center Prospective Phase 4 Study Comparing the Efficacy of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2 3 and 4 Pressure Injuries
This post-marketing study is being performed to assess the effectiveness of Altrazeal® Transforming Powder Dressing (“Altrazeal®” or “TPD”) manufactured by ULURU Inc. in patients with pressure injuries (sometimes also referred to as pressure sores or decubitus ulcers) compared to the current Standard of Care (SOC) therapies. TPD is manufactured, marketed, and used in the United States of America (US). ULURU Inc. is registered with the US Food and Drug Administration (FDA) and Altrazeal® is listed as a Class I 510(k) exempt medical device: “dressing, wound, hydrogel without drug and/or biologic.” (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=410757&lpcd=NAE) Under the supervision of a health care professional, TPD may be used in surgical, acute or chronic wounds including pressure injuries.Objectives:Primary: To compare the efficacy of TPD in reducing primary dressing changes in the treatment of non-infected Stage 2, 3 and 4 pressure injuries (PrIs).Secondary: Evaluate: 1) wound healing trajectories2) safety in the form of adverse events3) subject pain for sensate patientsExploratory: Evaluate: 1) resource utilization of TPD relative to SOC2) cost-effectiveness of TPD versus SOC3) budget impact analysis of adopting TPD4) wound quality of life5) research subject satisfaction6) other ad-hoc analyses as warranted
Rehabilitation for Parkinson’s Disease | NYU Langone Health
NYU Langone specialists offer rehabilitation services to improve the quality of life of people with Parkinson’s disease.
Diagnosing Amyotrophic Lateral Sclerosis | NYU Langone Health
NYU Langone doctors help to ensure an early diagnosis of ALS, to best maintain the quality of life of people with this condition.
Male Breast Cancer | NYU Langone Health
Perlmutter Cancer Center doctors use surgery, radiation therapy, and medication to manage male breast cancer.
Recovery & Support For Conjunctivitis | NYU Langone Health
NYU Langone specialists monitor eye health to prevent a recurrence of conjunctivitis.
Notice of Privacy Practices | NYU Langone Health
NYU Langone’s Notice of Privacy Practices describes how medical information about you may be used and disclosed, and how to get access to it.
Small Intestine Cancer | NYU Langone Health
Perlmutter Cancer Center doctors may manage small intestine cancer with surgery, radiation therapy, and chemotherapy.